Flow Therapeutics announced approval of its Flow-100 tDCS therapy for depression, which could expand access to non-pharmacologic care and will be available in the US in H2 2026.
Adolescents acquiring smartphones at 12 showed increased risk for depression, obesity and sleep disturbances, according to a study of more than 10,000 youths.